id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-254119-w6otllf5	Ingraham, Nicholas E	Immunomodulation in COVID-19	2020-05-04		.txt	text/plain	1403	77	33	Observational data show overlapping clinical features in severe COVID-19 with macrophage activating syndrome (MAS) and secondary haemophagocytic lymphohistiocytosis (HLH). Furthermore, the pathogenesis underlying SARS-CoV-2 involves several key pathways that can be manipulated, and use of these therapies can mitigate the propagation of an overdriven Figure: SARS-CoV-2 interaction with the inflammatory system and therapy targets within the system TLR4, AT1R, IL-6, IL-1, IL-18, type 1 IFNs, and IFN-γ receptor binding activates specific signalling cascades and translocation of nuclear transcription factors into the nucleus (blue ellipse), where they interact with their respective chaperones (NF-KB) or their targeting sequences on DNA (ISRE, GAS) to activate the production of multiple proteins including additional cytokines, chemokines, cell surface molecules, and more. In conclusion, as insight is gained into the clinical phenotypes associated with COVID-19, we propose JAK and IL-1 inhibitors as therapeutic targets warranting rapid investigation.	./cache/cord-254119-w6otllf5.txt	./txt/cord-254119-w6otllf5.txt